Immunotherapy has changed the treatment landscape for several cancers, but it is not a universal replacement for chemotherapy. It works by helping the immune system recognise or attack cancer cells, and its usefulness depends on the cancer type, stage and biological test results.
Patients exploring cancer immunotherapy in PCMC need an individual oncology evaluation before deciding whether this approach is appropriate.
How Immunotherapy Works
Cancer cells can sometimes avoid immune detection or send signals that suppress the body’s immune response. Certain immunotherapy medicines block these signals, allowing immune cells to respond more effectively.
Checkpoint inhibitors are among the best-known immunotherapies. They target proteins such as PD-1, PD-L1 or CTLA-4. Other immune-based approaches include monoclonal antibodies, cellular therapies and cancer vaccines, although their indications and availability differ.
Immunotherapy may be prescribed alone or combined with chemotherapy, targeted therapy or other treatments.
Who May Be Eligible
Eligibility is not based only on having an advanced cancer. The oncologist considers several factors:
- Confirmed cancer type and subtype
- Stage and sites of disease
- Biomarker findings
- Previous treatments and response
- Autoimmune conditions
- Organ-transplant history
- General health and organ function
- Evidence supporting immunotherapy for that diagnosis
Tests for PD-L1 expression, mismatch repair deficiency, microsatellite instability or other biomarkers may help predict whether particular patients could benefit. However, biomarker interpretation is cancer-specific. A result that guides treatment in one cancer may not have the same meaning in another.
Benefits and Limitations
Some eligible patients experience a durable response, meaning cancer control continues for a meaningful period. Immunotherapy may also provide an option when other treatments have stopped working.
However, not everyone responds. Some tumours lack the characteristics required for a particular medicine, while others continue to grow despite treatment. Response may take time, and scans can occasionally be difficult to interpret because immune activity may temporarily change the appearance of lesions.
An honest discussion should include the expected chance of benefit, available alternatives, treatment goal and how response will be assessed.
Immune-Related Side Effects
Immunotherapy side effects differ from typical chemotherapy effects. Because the treatment stimulates immune activity, it can cause inflammation in healthy organs.
Possible problems include:
- Skin rash or itching
- Diarrhoea or bowel inflammation
- Liver inflammation
- Thyroid or other hormonal changes
- Lung inflammation
- Joint symptoms
- Kidney problems
- Neurological effects
Most reactions are manageable when recognised early, but some can become serious. New breathlessness, persistent diarrhoea, severe abdominal pain, yellowing of the eyes, confusion, marked weakness or unusual headache should be reported promptly. Immunotherapy can cause mild or severe immune-related effects, including skin, bowel, lung and endocrine problems. American Cancer Society
Monitoring During Treatment
Before each dose, the oncology team reviews symptoms and may check blood counts, liver function, kidney function and thyroid levels. Imaging is performed at planned intervals rather than after every session.
Patients should tell every treating doctor that they are receiving immunotherapy. An immune-related reaction can develop during treatment or after it has ended, so a complete treatment history remains important.
Immunotherapy represents a meaningful advance, but its value comes from selecting the right patient and monitoring treatment responsibly. Decisions should be based on pathology, biomarkers, clinical evidence and the patient’s medical condition not on the assumption that newer treatment is automatically better.
Keywords
